Japanese scientists have developed an experimental cancer treatment strategy that uses carbon monoxide naturally produced inside cancer cells to manufacture anticancer compounds directly where they are needed. Researchers designed a specialized albumin–palladium catalyst that uses carbon monoxide as a chemical building block to trigger drug-forming reactions inside cancer cells. The team investigated this approach in four human cancer cell lines: liver cancer (HepG2), breast cancer (MCF7), lung cancer (A549), and cervical cancer (HeLa S3). Their experiments demonstrated that the catalyst could facilitate intracellular synthesis of anticancer compounds, potentially allowing drug production to occur preferentially in cancer cells rather than throughout the body.The researchers also investigated whether this approach could selectively damage cancer cells while reducing toxicity to healthy tissue. In liver cancer cells, the newly synthesized compounds produced dose-dependent anticancer effects, with approximately threefold greater toxicity toward cancer cells than normal human fibroblasts based on IC50 measurements. In breast cancer cells, the treatment significantly suppressed colony formation, indicating an impaired ability of cancer cells to survive and multiply. These findings suggest a potential strategy for developing cancer treatments that exploit differences in cellular chemistry to produce toxic compounds preferentially inside tumors.
In Album: Judy Gilford's Timeline Photos
Dimension:
1080 x 1350
File Size:
153.28 Kb
Be the first person to like this.
